Antidiabetics - Patent expiries and cost containment initiatives balanced by pipeline products

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-08-25

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The diabetes epidemic has contributed to growth in the antidiabetics market over the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment warrants that novel agents will have a place in the market.


Scope

  • Country specific event-driven sales forecasts for the period 2006-15 in the US, Japan, France, Germany, Italy, Spain and the UK, and a Global overview
  • Patient potential and prescribing trends overview of the antidiabetics market based on historical sales data and future key events
  • Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching
  • Case studies presenting the role that novel agents are likely to play and the balance between issues and opportunities in the diabetes market


    • Report Highlights
    Demographic trends will lead to increasing patient population. The antidiabetics market is set to continue increasing, driven by the dramatic increase in the prevalence of diabetes in the major markets. Additionally, the rising age of the population across all developed regions is creating an increased burden on health service providers and payers.

    The highest selling drug classes in the antidiabetics market are heavily genericized and thus will not generate the revenues needed for growing the market. Additionally, TZDs, one of the most lucrative classes, will face patent expiries in the coming decade. These events are expected to be counterbalanced by the introduction of novel agents.

    The diabetes market is characterized by high unmet need and treatment issues. However, these issues along with radical changes on the understanding of diabetes, have created an environment rich in opportunity. We expect that the growth of the diabetes market will be driven by the exchange of older, cheaper drugs for new more expensive agents.


    Reasons to Purchase

  • Quantify the future size and scope of the diabetes market and potential for new products
  • Analyze options to expand commercial potential through pursuit of new indications
  • Formulate successful launch strategies in a highly competitive market

    • Table of Contents

    Other users found this report page using the following search terms: diabetes patent expiry glucophage sales cost pioglitazone novorapid uk novolin containment

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.